New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain Commercial Launch Planned for Fourth Quarter 2021 Company to Host Investor
/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan).